Becton, Dickinson and Company $BDX Stock Sold by Cooke & Bieler LP

Posted by Stanley Muller on Oct 22nd, 2026

Cooke & Bieler LP lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 24.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 854,452 shares of the medical instruments supplier’s stock after selling 282,074 shares during the period. Becton, Dickinson and Company makes up about 2.3% of Cooke & Bieler LP’s holdings, making the stock its 8th largest holding. Cooke & Bieler LP’s holdings in Becton, Dickinson and Company were worth $152,947,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BDX. BlackRock Inc. bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $3,721,533,000. State Street Corp lifted its holdings in Becton, Dickinson and Company by 8.5% in the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after purchasing an additional 1,177,256 shares during the last quarter. First Eagle Investment Management LLC boosted its position in Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares during the period. Bank of America Corp DE bought a new stake in Becton, Dickinson and Company during the second quarter worth approximately $474,993,000. Finally, Legal & General Group Plc grew its holdings in Becton, Dickinson and Company by 1.5% during the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock valued at $318,050,000 after purchasing an additional 30,766 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent analyst reports. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Wolfe Research started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday. They issued an “outperform” rating on the stock. Finally, UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $185.07.

Check Out Our Latest Stock Report on BDX

Insiders Place Their Bets

In other news, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,906 shares of company stock valued at $1,265,855 in the last three months. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.3%

Becton, Dickinson and Company stock opened at $194.29 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The business’s 50-day simple moving average is $184.73 and its 200-day simple moving average is $164.54. The firm has a market capitalization of $53.53 billion, a PE ratio of 58.52, a PEG ratio of 13.07 and a beta of 0.21. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $195.99.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the firm earned $3.68 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.